Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Trial To Investigate The Effects Of Three Dose Levels Of CIT-013 On Disease Activity In Patients With Moderately Active Rheumatoid Arthritis.

NCT06567470 is registered in ClinicalTrials.gov with Citryll BV as lead sponsor.

NCT NCT06567470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06567470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Trial To Investigate The Effects Of Three Dose Levels Of CIT-013 On Disease Activity In Patients With Moderately Active Rheumatoid Arthritis.
Lead sponsor
Citryll BV
Phase
Phase 2
Overall status
Recruiting
Start date
July 29, 2025
Completion date
July 31, 2027
Enrollment
88 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis